GSK189075

Phase 2Small molecule

GSK

GSK189075 is one of 116 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

115

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Weight LossActive, not recruiting

Type 1 Diabetes MellitusActive, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

Weight LossPhase 1

Active, not recruiting

Type 1 Diabetes MellitusPhase 2

Active, not recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Tanzeum

GSK

Preclinical

10 2

Insulin 320

Novo Nordisk

Preclinical

43 3

GSK189075

GSK

Phase 2

2 4

Adenocard

Astellas

Preclinical

1 5

Myrbetriq

Dostinex

Golytely

Lantus

6 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 10

Lixisenatide

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Drug2 trials

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Completed· GSK logo

GSK·Phase 1·NCT00559884·36 enrolled

A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy Volunteers

Completed· GSK logo

GSK·Phase 1·NCT00501930·12 enrolled

Type 2 Diabetes Mellitus2 trials

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

Completed· GSK logo

GSK·Phase 2·NCT00495469·250 enrolled

Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)

Completed· GSK logo

GSK·Phase 2·NCT00500331·334 enrolled

Female1 trial

A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers

Completed· GSK logo

GSK·Phase 1·NCT00504816·22 enrolled

Drug Interactions1 trial

Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes

Completed· GSK logo

GSK·Phase 1·NCT00376038·13 enrolled

Type 2 Diabetic Patients1 trial

GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients

Completed· GSK logo

GSK·Phase 2·NCT00291356·45 enrolled

7 more indications

Function1 trial

A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function

Completed· GSK logo

GSK·Phase 1·NCT00501462·29 enrolled

Adult1 trial

A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults

Completed· GSK logo

GSK·Phase 1·NCT00532610·78 enrolled

Weight loss1 trial

Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs

Completed· GSK logo

GSK·Phase 1·NCT00494767·27 enrolled

Oral1 trial

A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers

Completed· GSK logo

GSK·Phase 1·NCT00501397·22 enrolled

Metformin1 trial

A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin

Completed· GSK logo

GSK·Phase 1·NCT00519480·50 enrolled

Type 1 Diabetes Mellitus1 trial

A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus

Completed· GSK logo

GSK·Phase 2·NCT00575159·10 enrolled

ESS1 trial

A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects

Completed· GSK logo

GSK·Phase 1·NCT00625859·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for GSK189075. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK189075 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK189075. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

GSK189075

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Drug2 trials

Type 2 Diabetes Mellitus2 trials

Female1 trial

Drug Interactions1 trial

Type 2 Diabetic Patients1 trial

Function1 trial

Adult1 trial

Weight loss1 trial

Oral1 trial

Metformin1 trial

Type 1 Diabetes Mellitus1 trial

ESS1 trial

References

Drug Info

Quick Facts

Related News